ZHB N004
Alternative Names: ZHB-N004Latest Information Update: 29 Aug 2025
At a glance
- Originator Jiangsu ZonHon Biopharma Institute
- Class Antidepressants
- Mechanism of Action
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Depressive disorders
Most Recent Events
- 23 Jul 2025 Preclinical trials in Depressive disorders in China (unspecified route) before July 2025 (Jiangsu Zonhon Biopharma Institute pipeline, July 2025)